In preparation for the global distribution of Covid-19 vaccines, Swissport puts facilities and processes to the test. Swissport’s team in Brussels demonstrated its ability to handle temperature sensitive air cargo in a dry-run under real-conditions and under the eyes of experts and trade reporters at our state-of-the-art Swissport Pharma Center.

Swissport around the world is busy establishing operational readiness for the handling of highly temperature-sensitive vaccines. Vaccines and indeed many pharmaceuticals require rigorous temperature control throughout the entire supply chain. While some types Covid-19 vaccines might only call for temperatures around -20°C or in a range from 2°-8°C, others will likely require extremely low temperatures in the range of -70°C.

In collaboration with Brussels Airport, Air Cargo Belgium and Hazgo, Swissport demonstrated its ability to handle highly temperature-sensitive air cargo at its state-of-the-art 3,620 sqm Pharma Center in Brussels. Two separate shipments were delivered to the facility, which is part of an end-to-end cool chain. One shipment arrived in a container cooled to -70°C, while the other shipment was transported in a more conventional 2°-8°C temperature range. Swissport’s top-notch infrastructure, combined with know-how regarding dry-ice handling allows for a seamless temperature-control throughout the entire airport handling process, from the acceptance at the cargo warehouse to the transport on the apron with special vehicles and right into the aircraft.

“Today’s demonstration shows that, thanks to the successful and long-standing collaboration with our airport partners, Swissport is ready to play its part in the logistical challenge to globally distribute a Covid-19 vaccine,“ says Koen Gouweloose, Head of Swissport Cargo Services Belgium. “We are ready.”